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1 Introduction 
A monolithic support consists of a continuous bed that 
has both large through-pores to permit solvent flow and 
smaller side pores for analyte interactions with the sta-
tionary phase. These properties tend to give monoliths 
better mass transfer properties, higher permeability, and 
lower back-pressures than traditional particulate sup-
ports for HPLC [1]. Monolithic supports have already 
been used in many types of LC [2–5]. These supports 
have also recently become of interest for use in affinity 
chromatography, a method in which the stationary phase 
is a biological-related ligand; the resulting combination of 
affinity ligands and monolithic supports is referred to as 
affinity monolith chromatography (AMC) [6]. 
Various support materials have been considered for 
use in AMC, including GMA/EDMA co-polymers [7–17], 
agarose [18, 19], and cryogels [20, 21], among others. Sil-
ica monoliths are another set of supports that have been 
explored for use in AMC [22–26]. Silica monoliths are at-
tractive for AMC because they combine the benefits of 
monolithic supports with the use of a silica-based sup-
port, which makes it possible to adapt many of the immo-
bilization schemes already employed in the creation of af-
finity columns using silica particles [6, 26, 27]. Previous 
applications of silica monoliths in AMC have included 
their use in the chiral separations of drugs using immo-
bilized serum proteins [23, 26], the screening of enzyme 
inhibitors [28], the high-throughput analysis of enzymes 
and proteins [29], and separations based on immobilized 
metal-ion affinity chromatography [30]. 
Another possible application of AMC is in the analysis 
of drug–protein interactions. HSA is the most abundant 
plasma protein in humans and is known to bind to var-
ious drugs and hormones, affecting the transport, distri-
bution, metabolism, and excretion of such substances [31–
33]. There are two major binding sites for drugs on HSA, 
which are referred to as Sudlow sites I and II [31]. Two 
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drugs that have well-known binding properties at these 
sites are warfarin and carbamazepine (see Figure 1). War-
farin is an anticoagulant drug known to bind to Sudlow 
site I [31, 34], while carbamazepine is an anticonvulsant 
drug that binds to Sudlow site II [35–37]. The binding of 
both of these drugs has previously been examined us-
ing traditional HPLC affinity columns in which HSA has 
been immobilized to silica particles [34, 36, 38– 40]. 
HPLC affinity columns have been shown in previous 
studies to be useful in the analysis of drug–protein in-
teractions, such as those that occur in blood [41, 42]. The 
results obtained when using immobilized HSA in stan-
dard HPLC columns give good agreement with data ob-
tained by reference methods using soluble HSA (e.g., 
equilibrium dialysis and ultrafiltration) [39, 41]. Exper-
iments that can be conducted with these columns range 
from the measurement of percentage binding and bind-
ing affinity to kinetic studies and drug–drug competi-
tion studies [39, 40]. The advantages of using HPLC af-
finity columns for this work include the ability to reuse 
the same protein preparation for many experiments, 
the good precision and accuracy of this approach, and 
the relative speed at which binding studies can be con-
ducted [41, 42]. 
This study will examine the creation and use of affinity 
microcolumns containing silica monoliths for use in the 
analysis of drug–protein interactions. HSA will be used 
as the model protein and R-warfarin or carbamazepine 
will be the drugs employed in this study. Retention fac-
tors and plate heights will be measured for these systems, 
representing the main parameters used in zonal elution 
studies to examine drug–protein binding on traditional 
HPLC affinity columns [39–41, 43]. A comparison will 
also be made between affinity microcolumns containing 
silica monoliths and those with silica particles. This infor-
mation will be used to determine the feasibility of using 
affinity microcolumns and silica monoliths for the high-
throughput analysis of drug–protein interactions and to 
identify chromatographic conditions that are suitable for 
such work. 
2 Experimental
2.1 Reagents
HSA (Cohn fraction V, essentially fatty acid free, ≥96% 
pure), carbamazepine (≥98% pure), and R-warfarin (≥97% 
pure) were from Sigma (St. Louis, MO, USA). Nucleo-
sil Si-300 silica (300 Å pore size, 7 μm particle size) was 
from Macherey Nagel (Düren, Germany). Reagents for 
the bicinchoninic acid (BCA) protein assay were from 
Pierce (Rockford, IL, USA). All buffers and aqueous so-
lutions were prepared using water from a Nanopure sys-
tem (Barnstead, Dubuque, IA, USA) and filtered using 
Osmonics 0.22 μm nylon filters from Fisher (Pittsburgh, 
PA, USA). 
2.2 Apparatus
The Chromolith Performance Si column (4.6 mm i.d. × 10 
cm) was donated by Merck KGaA (Darmstadt, Germany). 
From this column, 1, 3, and 5 mm long pieces were cut 
to make shorter silica monolith columns by using a lathe. 
Reagents to activate the silica monolith and immobilize 
HSA were applied using a Beckman System Gold 118 Sol-
vent Module pump (Fullerton, CA, USA). The silica parti-
cle-based columns (3 mm × 2.1 mm i.d.) were packed us-
ing an Alltech slurry packer (Deerfield, IL, USA). 
The chromatographic system consisted of an isocratic 
HPLC PU-2080 Plus pump and a UV-2075 Plus detector 
from Jasco (Easton, MD, USA). Injection was carried out 
by using a six-port Rheodyne Lab Pro valve (Cotati, CA, 
USA) and a 5 μL sample loop. An Alltech water jacket 
and a circulating water bath from Fisher were used to 
control the temperature in the chromatographic columns. 
Chromatographic data were collected and processed us-
ing in-house programs written in LabView 5.1 (National 
Instruments, Austin, TX, USA). 
2.3 Preparation of HSA silica monoliths
Each silica monolith was first converted into a diol-
bonded form, as described previously [23]. To do this, a 
1–5 mm long section of the original silica monolith was 
cut and assembled into a column housing made of delrin. 
Each of these silica monoliths was first washed with 0.10 
M, pH 5.5 sodium acetate buffer for 40 min at 0.5 mL/
min (unless otherwise indicated, the following steps were 
conducted at room temperature). Pure 3- glycidoxyprop-
yltrimethoxysilane was passed through the monolith for 
Figure 1. Structures of (a) carbamazepine and (b) warfarin. 
The asterisk shows the location of the chiral center in warfarin. 
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50 min at 0.2 mL/min, as used previously for longer sil-
ica monoliths in reference [23]. After sealing both ends, 
the monolith column was placed in a water bath at 97°C 
for 5 h. A solution of 0.10 M, pH 5.5 sodium acetate buf-
fer was used to wash the column for 50 min at 0.1 mL/
min and pure 3-glycidoxypropyltrimethoxysilane was 
again passed through the column for 50 min at 0.1 mL/
min to ensure maximum diol coverage. The column ends 
were sealed and the column was placed in a water bath 
at 97°C for 5 h. The column was removed from the water 
bath and washed with water for 4 h at 0.2 mL/min. A pH 
3.0 solution of dilute sulfuric acid in water was passed 
through the column for 50 min at 0.2 mL/min. The col-
umn was then again sealed at both ends and placed in a 
water bath at 70°C for 3 h. All of the resulting diol silica 
monolith columns were washed with water at 0.2 mL/
min for over 5 h. Some of these columns were used for 
HSA immobilization while others were used as control 
columns in further studies. 
HSA was immobilized onto the diol silica monolith 
by using the Schiff base method (see Figure 2) [23]. In 
this method, a 90% v/v acetic acid solution in water was 
passed through each column for 4 h at 0.2 mL/min. A so-
lution of 0.5 g/mL periodic acid in 90% acetic acid in wa-
ter was then passed through the column in the dark for 7 
h at 0.2 mL/min to oxidize the diol groups and form al-
dehyde groups. The column was washed with water for 
8 h at 0.2 mL/min. A 10 mL solution containing 50 mg 
HSA and 25 mg sodium cyanoborohydride (a mild re-
ducing agent) in 1.5 M, pH 6.0 potassium phosphate buf-
fer was circulated through each column for 24 h at 0.5 mL/ 
min. Separate HSA solutions were used in this step and 
the next for each column. The sodium cyanoborohydride 
was used to reduce the reversible Schiff bases formed be-
tween amine groups on HSA and aldehyde groups on the 
support, resulting in stable secondary amine linkages (be-
cause it is a mild reducing agent, the sodium cyanoborohy-
dride did not reduce the original aldehydes prior to their 
reaction with amines). A second fresh 12 mL solution of 60 
mg HSA and 30 mg sodium cyanoborohydride in the same 
pH 6.0 buffer was circulated through the column for 65 h 
at 0.5 mL/min. A 5 mL solution of 0.10 M, pH 8.0 potas-
sium phosphate buffer containing 1 mg/mL sodium bo-
rohydride (a strong reducing agent) was applied to each 
column for 1.5 h at 0.05 mL/min using a syringe pump 
(Harvard Apparatus, Holliston, MA, USA), with this solu-
tion being used to reduce any remaining aldehydes on the 
support. The monolith columns were then washed with 
0.10 M, pH 8.0 potassium phosphate buffer containing 0.5 
M sodium chloride, which was passed through each col-
umn for 50 min at 0.2 mL/min, followed by an additional 
washing with 0.067 M, pH 7.4 potassium phosphate buf-
fer for 1.5 h at 0.5 mL/min. The resulting HSA silica mono-
liths were stored in this last buffer at 4°C until use. These 
columns were used within a period of three months. Simi-
lar but longer silica monoliths have been found to be stable 
for at least four months under the storage and experimen-
tal conditions used in this study [23]. 
The protein content in the HSA silica monoliths was 
estimated as described in ref. [23] by measuring the re-
tention factor for 5 μL injections of 30 μM carbamazepine 
in the presence of pH 7.4, 0.067 M potassium phosphate. 
Similar injections were made onto the control columns to 
correct for any nonspecific binding of carbamazepine to 
the support. It was found that nonspecific binding typi-
cally made up 21–33% of the total retention seen on the 
HSA silica monoliths. The estimated protein coverage of 
these supports was 1.8 (±0.1) μmol HSA/g support [23]. 
This result corresponded to a protein content in each col-
umn of 0.36 (±0.02) μmol HSA/mL. 
2.4 Preparation of HSA silica particles
To prepare the particle-based supports, Nucleosil Si-
300, 7 μm particle size silica was converted into a diol-
bonded form, as described previously [44]. A particle 
size of 7 μm was chosen for this work because it has been 
commonly used in the past to prepare immobilized HSA 
for use in HPLC affinity columns for drug–protein bind-
ing studies [34, 36, 38–40]. HSA was immobilized onto 
part of this diol silica by using the Schiff base method 
[45], with the remainder of the diol silica being used to 
prepare a control support in which no HSA was added 
to the silica. In the Schiff base method, 0.5 g of diol sil-
ica was combined with 0.5 g periodic acid in 10 mL of a 
90% v/v solution of acetic acid in water, with this mix-
Figure 2. Preparation of a HSA silica 
monolith by the Schiff base method. 
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ture then being allowed to react for 2 h with shaking. The 
resulting aldehyde- activated silica was then washed six 
times with water and three times with 0.10 M, pH 6.0 po-
tassium phosphate buffer. 
The aldehyde-activated silica from the previous step 
was combined with a 5 mL solution of 0.10 M, pH 6.0 po-
tassium phosphate buffer containing 50 mg HSA and 25 
mg sodium cyanoborohydride. This mixture was allowed 
to shake on a rotary mixer at 4°C for 6 days. The HSA sil-
ica that this reaction produced was washed four times 
with 0.10 M, pH 8.0 potassium phosphate buffer and 
slowly combined with three portions of 12 mg sodium 
borohydride, which were added over the course of 90 
min while the mixture was allowed to react at room tem-
perature. This slurry was washed three times with 0.10 
M, pH 8.0 potassium phosphate buffer that contained 0.5 
M sodium chloride, followed by two additional washings 
with 0.067 M, pH 7.4 potassium phosphate buffer. The fi-
nal HSA silica and corresponding control support were 
stored in 0.067 M, pH 7.4 potassium phosphate buffer at 
4°C until use. 
Small portions of the HSA silica and control support 
were washed several more times with water and dried 
under vacuum at room temperature. These dried sam-
ples were analyzed in triplicate using a BCA protein as-
say [46], with HSA being employed as the standard and 
the control support being used as the blank. The final pro-
tein content of the HSA silica was found to be 0.76 (±0.05) 
μmol HSA/g support, which corresponded to a protein 
content of 0.34 (±0.02) μmol HSA/mL. The remaining 
portions of the original HSA silica and control support 
were downward slurry packed at 4000 psi (28 MPa) for 40 
min into stainless steel columns using 0.067 M, pH 7.4 po-
tassium phosphate buffer as the packing solution. These 
columns were stored in pH 7.4, 0.067 M potassium phos-
phate buffer at 4°C until use. These columns were used 
within a period of 3 months and are typically stable for 
up to one year under the storage and experimental condi-
tions used in this study [47]. 
2.5 Chromatographic studies
The mobile phase used throughout these studies was 
pH 7.4, 0.067 M potassium phosphate buffer. The col-
umn temperature was maintained at 37.0 (±0.1)°C dur-
ing all experiments. A 5 μL injection volume was used 
for all samples, with each sample being injected in trip-
licate under all of the tested chromatographic condi-
tions. All samples were prepared in 0.067 M, pH 7.4 po-
tassium phosphate buffer and stored at 4°C when not in 
use. Solutions of R-warfarin were stored at 4°C for up to 
one week, and solutions of carbamazepine were stored at 
4°C for several weeks; both of these analytes have been 
shown previously to be stable under such conditions [36, 
38]. All mobile phases were degassed for 25 min prior to 
use. The following detection wavelengths were used: 308 
nm for R-warfarin and 255 nm for carbamazepine. The 
void time of the system was determined by injecting a 25 
μM sample of sodium nitrate that was prepared in the 
mobile phase. The elution of sodium nitrate was moni-
tored at 205 nm. 
A 30 μM carbamazepine sample was chosen for this 
work because no significant change was noted in the 
measured retention of this analyte when over two-fold 
higher or lower concentrations were used, thus indicating 
that linear elution conditions were present for this sam-
ple. A 20 μM R-warfarin sample was utilized for similar 
reasons. The central moment and second moment (i.e., 
moment 2, or the variance) were found for each peak by 
using Peakfit 4.12 (Systat Software, San Jose, CA, USA) 
along with the linear progressive baseline, Savitsky–Go-
lay smoothing, and EMG peak fit settings of this software. 
The central moment was used to determine the reten-
tion factor, and the second moment was used to measure 
band-broadening and to calculate plate heights. The void 
time of the system, as required for retention factor mea-
surements, was determined by injecting 25 μM sodium 
nitrate. Similar injections were made with no column 
present in the system to correct for the extra-column void 
time of the system and extra-column band-broadening. 
3 Results and discussion 
3.1 Retention of carbamazepine on HSA microcolumns 
using silica monoliths
Zonal elution measurements of drug retention are often 
made on HPLC affinity columns to estimate the percent-
age binding of a drug to an immobilized protein such as 
HSA [41]. This approach is also used to examine the ef-
fect of a competing drug or solute on the binding by a site 
selective probe to the column [34, 41, 47] and to examine 
the effect of temperature or mobile phase composition on 
drug–protein interactions [39, 41]. The use of zonal elu-
tion conditions in these experiments is applicable to the 
study of solute–ligand systems with weak-to-moderate 
strength interactions (i.e., as association equilibrium con-
stant of 106 M–1 or lower) and relatively fast association/ 
dissociation kinetics; these conditions make this approach 
an example of “weak affinity chromatography” (see refer-
ences [39–41, 43] for more details). Carbamazepine is one 
drug that has been used as a probe for Sudlow site II in 
binding studies conducted on HSA columns [36]. Carba-
mazepine has an association equilibrium constant of 5.3 
× 103 M–1 at pH 7.4 and 37°C with HSA [36]. This bind-
ing strength is typical of that seen for many drugs with 
this protein [31, 42], making carbamazepine a good gen-
eral model for the work that was conducted in this study. 
This drug was used to see how varying both column size 
and flow rate would affect binding studies that might be 
made on affinity microcolumns. 
2780 yo o & ha g e i n Jo u r n a l o f Se p a r a t i o n Sc i e n c e  32 (2009) 
Figure 3 shows chromatograms that were obtained at 
0.5 mL/min for injections of carbamazepine on 4.6 mm 
i.d. HSA microcolumns of various lengths made from 
silica monoliths. The retention times noted for carbam-
azepine were 33, 49, and 64 s on the 1, 3, and 5 mm long 
microcolumns, respectively. These retention times are 
significantly shorter than the retention time of 10.6 min 
that would be expected for carbamazepine at 0.5 mL/min 
on a 10 cm × 4.6 mm i.d. HPLC silica monolith containing 
HSA, based on data given in reference [23]. 
The back pressures measured for the 3 mm long HSA 
affinity microcolumn made from a silica monolith ranged 
from 256 psi (1.8 MPa) at 0.5 mL/min to 825 psi (5.7 MPa) 
at 4.0 mL/min, with almost two-fold lower back pres-
sures being recorded on the 1 mm long microcolumn. In 
comparison, a 4.6 mm i.d. × 5 cm HSA column based on 
silica particles has been reported to give a back pressure 
of 995 psi (6.9 MPa) at 3.0 mL/min [23]. The relatively 
low back pressures of the silica monoliths and higher 
flow rates that could be employed with these columns 
made it possible to further reduce the time needed for the 
elution of drugs from these columns. In this case, a flow 
rate of 4.0 mL/min gave retention times of 5.6– 8.3 s for 
carbamazepine on the 1 to 5 mm long affinity microcol-
umns. These values are 50-fold lower than the typical re-
tention time that would be expected for this drug at 0.5 
mL/min on a 10 cm × 4.6 mm i.d. HSA column contain-
ing a silica monolith [23]. 
Figure 4 shows how the retention factor for carbam-
azepine changed with flow rate on the 1 and 5 mm × 4.6 
mm i.d. HSA microcolumns containing a silica mono-
lith. Similar results were obtained on the 3 mm × 4.6 mm 
i.d. HSA microcolumn. It is desirable in zonal studies of 
drug–protein binding to have a retention factor that does 
not vary significantly with flow rate. Under these condi-
tions, the mean position of the peak is typically assumed 
 
 
 
 
 
 
 
 
 
 
to represent a local equilibrium between the drug and 
the immobilized protein. This assumption makes it pos-
sible to estimate the extent of drug–protein binding or to 
study the equilibrium processes involved in this binding 
by using the measured retention factor. It was found in 
this report that similar retention factors were obtained 
for carbamazepine even when going from the 5 mm × 
4.6 mm i.d. HSA microcolumn to the 1 mm × 4.6 mm 
i.d. HSA microcolumn. For instance, the average reten-
tion factors measured at flow rates of 0.25–2.0 mL/min 
on the 5 mm versus 1 mm long columns were 1.7 (±0.1) 
and 2.4 (±0.2), respectively, while the average retention 
factors determined at 0.25–6.0 mL/min were 2.1 (±0.5) 
and 2.5 (±0.4). Comparable results were seen with the 3 
mm long microcolumn. Small batch-to-batch differences 
in protein coverage did lead to some corresponding col-
umn-to-column variations in the retention factors, such 
as those at lower flow rates for the 1 and 5 mm column 
results. However, the results in Figure 4 do clearly indi-
cate that microcolumns in this size range could be used 
in retention factor measurement for drug–protein bind-
ing studies. 
The use of smaller microcolumns has the obvious ad-
vantage of allowing faster analysis times by providing 
shorter column residence times and lower column back-
pressures. One disadvantage noted in Figure 4 in the 
Figure 3. Chromatograms obtained for injections of 30 μM car-
bamazepine at 0.5 mL/min onto 4.6 mm i.d. HSA silica mono-
liths with lengths (from bottom-to-top) of 1, 3, or 5 mm. The 
experimental conditions are given in the text. 
Figure 4. Retention factors measured at various flow rates for 
injections of 30 μM carbamazepine onto 4.6 mm i.d. HSA sil-
ica monoliths with lengths of (a) 5 mm or (b) 1 mm. The exper-
imental conditions are given in the text. The error bars repre-
sent a range of ±1 S.D. 
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use of very short microcolumns for drug-binding stud-
ies is that there is a loss in precision during retention fac-
tor measurements as the column length is decreased. The 
5 mm long HSA microcolumns gave a precision in these 
measurements between 0.25 and 6.0 mL/min that ranged 
from ±0.5 to ±4% (average, ±2.6%), while the precision for 
the 3 mm column under the same conditions was ±3 to 
±16% (average, ±8%). In comparison, the 1 mm column at 
these same flow rates had a precision of ±7 to ±33% (av-
erage, ±21%) for the measured retention factors of carba-
mazepine. This decrease in precision was related to the 
faster elution times of carbamazepine from the shorter 
microcolumns, which lowered the degree of certainty as-
sociated with the central moments determined for the 
corresponding peaks.
Besides providing shorter analysis times, affinity mi-
crocolumns also require a smaller amount of immobilized 
protein or ligand than traditional HPLC affinity columns. 
For instance, the protein content of a 3.5 cm × 2.1 mm i.d. 
HSA silica particle-based affinity column (i.e., one of the 
smaller columns used in previous studies) has been re-
ported to be 36 nmol HSA [47]. The 1 and 3 mm × 4.6 mm 
i.d. affinity microcolumns used in this current report con-
tained approximately 1.2 to 3.5 nmol HSA, or 10–30 fold 
less protein than the column in reference [47]. These mi-
crocolumns also contained roughly 33–100-fold less pro-
tein than a 10 cm × 4.6 mm i.d. HPLC silica monolith that 
was used in a previous study for the immobilization of 
HSA [23]. 
One possible disadvantage of having lower protein 
content in an affinity column is that smaller amounts 
of sample must be injected to avoid column overload-
ing and concentration-dependent changes in retention 
(i.e., nonlinear elution effects). It was found in this re-
port that samples containing up to 80 μM carbamaze-
pine gave less than a 1.9–5.1% change in the measured 
retention factor. This result indicated that such nonlin-
ear effects were not a significant problem at the typical 
concentration of 30 μM carbamazepine that was used 
throughout this study for all of the affinity microcol-
umns (similar results were obtained for R-warfarin later 
in this report). 
3.2 Band-broadening of carbamazepine on HSA microcol-
umns using silica monoliths
The band-broadening and width of peaks obtained in 
zonal elution studies with affinity columns are also of in-
terest because this information can be used to learn about 
the kinetics of drug–protein binding [41, 42]. This tech-
nique again works well for solute –ligand systems with 
weak-to-moderate strength interactions and relatively 
fast association/dissociation kinetics, such as those that 
occur between many drugs and small solutes with HSA 
[41, 43]. This type of experiment requires the ability to 
measure plate heights over a wide range of flow rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The next series of studies in this report examined the pos-
sible use of affinity microcolumns and silica monoliths for 
such work. 
Figure 5 shows some typical plate height plots that 
were generated using the 1 and 5 mm long HSA microcol-
umns. Comparable plots were obtained for the 3 mm long 
column. The plate heights measured for these columns 
were all between 0.5 and 0.8 mm at 37°C and showed no 
appreciable change over the linear velocities that were 
examined in this report. These values are comparable to 
plate heights of 0.4–0.7 mm that have been reported at 
25°C on a 10 cm × 4.6 mm i.d. HSA silica monolith us-
ing l-tryptophan as the analyte (i.e., a solute that binds 
to Sudlow site II with a similar strength to that of carba-
mazepine) [23]. The little or no change seen in the plate 
height over the linear velocities that were tested in this re-
port indicates that these conditions were obtained over 
the region in which contributions from stationary phase 
mass transfer and stagnant mobile phase mass transfer 
dominate the plot in Figure 5. 
The corresponding number of theoretical plates for 
carbamazepine on the HSA microcolumns was approx-
imately 1–2, 3–6, or 8–9 for the 1, 3, and 5 mm long col-
umns, respectively. Given the small number of theoret-
ical plates that were present on the 1 mm long column, 
it was somewhat surprising to see that the measured 
plate heights for this column gave such good agreement 
with the values for the longer 3 and 5 mm HSA columns 
in this report, as well as with data for a 10 cm HSA sil-
Figure 5. Plate height plots obtained for injections of 30 μM car-
bamazepine onto 4.6 mm i.d. HSA silica monoliths with lengths 
of (a) 5 mm or (b) 1 mm. The experimental conditions are given 
in the text. The error bars represent a range of ±1 S.D. 
2782 yo o & ha g e i n Jo u r n a l o f Se p a r a t i o n Sc i e n c e  32 (2009) 
ica monolith that has been used in previous studies [23]. 
This may reflect the presence of relatively fast association 
and dissociation kinetics for carbamazepine with immo-
bilized HSA, as has been previously observed for l-tryp-
tophan [48].
One disadvantage of using affinity microcolumns 
to determine plate heights is that there was a clear de-
crease in the precision of these measurements as the col-
umn length was decreased, especially when going from 
the 5 mm column to the 1 mm long column. For the 5 mm 
long column, the precision of the plate heights in Figure 
5 ranged from ±1.2 to ±15%, with an average precision of 
±7%. The 3 mm long column gave similar precision val-
ues, which ranged from ±.4 to ±%, with an average pre-
cision of ±5%. In comparison to these results, the 1 mm 
long column gave precision that varied between ±3 to 
±29%, with an average precision of ±10%. Although high 
precision plate height measurements may require lon-
ger columns [41–43], these data do suggest that affin-
ity microcolumns can be used to provide good estimates 
of plate heights for at least the preliminary screening of 
drug–protein interaction kinetics while also minimizing 
the amount of time required for such studies. 
3.3 Retention of warfarin on HSA microcolumns using 
silica monoliths
Warfarin is frequently used in zonal elution studies 
as a probe for Sudlow site I in drug competition stud-
ies on HSA columns [34, 47]. The binding of warfarin 
with HSA columns has been previously characterized in 
terms of both the equilibrium constant [39] and rate con-
stants [40] for this interaction. One challenge in work-
ing with warfarin is its strong binding for HSA. For in-
stance, the association equilibrium constant of an HSA 
column for R-warfarin has been found to be 2.1 × 105 
M–1 at pH 7.4 and 37°C, with S-warfarin having slightly 
stronger binding under these conditions [38, 40]. Many 
previous studies using HSA in HPLC columns have em-
ployed columns with lengths of 4–10 cm, which give rel-
atively long retention times for warfarin (e.g., 25–150 
min) due to the strong binding of this drug to these col-
umns [23, 34, 38, 47]. The use of an affinity microcolumn 
is particularly attractive for this drug because it could 
significantly reduce the time required in experiments 
that use either R- or S-warfarin as site selective probes 
for HSA when examining the binding of new drug can-
didates to this protein [34].
Some typical chromatograms are shown in Figure 6 for 
injections of R-warfarin onto a 3 mm × 4.6 mm i.d. HSA 
microcolumn containing a silica monolith. The retention 
times noted for R-warfarin on this microcolumn were 5.4 
min at 1.0 mL/min and 9.5 min at 0.5 mL/min. These re-
tention times are shorter than the 150–160 min reten-
tion time that was observed earlier for R-warfarin at 1.0 
mL/min on a 10 cm × 4.6 mm i.d. HPLC silica monolith 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
containing HSA [23]. These retention times are also lower 
than values of 12–15 min or 20–25 min, respectively, that 
have been obtained at 0.5 mL/min for 5 cm × 4.1 mm i.d. 
or 10 cm × 4.1 mm i.d. HSA columns using silica parti-
cles [38, 49]. Similar results would be expected for S-war-
farin, which typically has a retention factor that is slightly 
higher than for R-warfarin under the mobile phase and 
temperature conditions used in this study [39]. Race-
mic warfarin was not used in this current report because 
it was expected from previous results with larger HSA 
columns that the affinity microcolumns would not have 
sufficient resolution to separate R- and S-warfarin, thus 
complicating the determination of retention and band-
broadening for such analytes if a racemic mixture was 
used as the sample [23, 39]. 
The relatively low back-pressures and high flow rates 
that could be used with silica monoliths made it possi-
ble to further reduce the time needed for the elution of R-
warfarin. In this case, a flow rate of 4.0 mL/min on the af-
finity microcolumn gave a retention time of 1.37 min for 
R-warfarin, which was at least ten-fold lower than the 
typical retention times noted at 0.5 mL/min on 4.1 mm 
i.d. × 4.5 cm HSA columns containing silica particles [49] 
and over 100-fold lower than the retention time seen at 
1.0 mL/min on a 10 cm × 4.6 mm i.d. HPLC silica mono-
lith containing HSA [23]. 
Figure 7a shows how the retention factor for R-war-
farin changed with flow rate on the 3 mm × 4.6 mm i.d. 
HSA microcolumn containing a silica monolith. This re-
tention factor had an average value of 65 (±7) in going 
from 0.5 to 4.0 mL/min, with a variation of only 7% be-
ing noted at flow rates ranging from 1 to 4 mL/min. The 
precision of retention factors measured at the individual 
flow rates in this range varied from ±0.9 to ±4.0%, with 
an average of ±2%. These results again indicated that an 
affinity microcolumn of this size and containing a silica 
monolith could be used to provide reproducible retention 
factors for drug–protein binding studies. It is interesting 
Figure 6. Chromatograms obtained at various flow rates for 
injections of 20 μM R-warfarin on a 3 mm × 4.6 mm i.d. HSA 
silica monolith column. The experimental conditions are given 
in the text. 
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to note that the precision seen for the retention factors 
of R-warfarin on the 3 mm × 4.6 mm i.d. HSA microcol-
umn was much better than that obtained earlier for carba-
mazepine on the same column. This difference occurred 
because of the much higher retention of R-warfarin ver-
sus carbamazepine, which made it easier to measure the 
retention factor for the former analyte. The same general 
trend would be expected on other affinity microcolumns 
when comparing drugs that have strong binding to an 
immobilized protein versus those with weak-to-moderate 
binding. 
3.4 Band-broadening of warfarin on HSA microcolumns 
made with silica monoliths
The band-broadening of warfarin on the HSA micro-
columns was next examined. This topic was of interest 
because measurements of band-broadening have been 
previously employed to examine the kinetics of R-warfa-
rin association and dissociation on traditional HPLC af-
finity columns containing HSA [40]. 
Figure 8 shows a plate height plot obtained on the 3 
mm × 4.6 mm i.d. HSA microcolumn containing a sil-
ica monolith. This plate height plot was fairly flat, with 
a variation of only ±12% being seen in the measured 
plate heights between linear velocities of 0.01 and 0.05 
cm/s (i.e., flow rates of 0.5 to 4.0 mL/min). Similar plate 
height plots have been observed at linear velocities 
spanning from roughly 0.12 to 0.35 cm/s for the injec-
tion of racemic warfarin on a 10 cm × 4.6 mm i.d. HPLC 
silica monolith containing HSA [23]. The small change 
noted in the plate height with linear velocity in Figure 
8 indicates that these conditions were obtained over the 
region in which contributions from stationary phase 
mass transfer and stagnant mobile phase mass transfer 
dominate.
The plate heights measured here, which were around 
0.2 mm at 37°C, were slightly higher than values of 0.04–
0.06 mm that have been reported at 25°C for R-warfarin 
on the 10 cm × 4.6 mm i.d. HSA silica monolith used in 
reference [23]. The corresponding number of theoreti-
cal plates for R-warfarin on the 3 mm × 4.6 mm i.d. HSA 
silica monolith was 11.5 to 15.2 at the given flow rates. 
The precision of the plate heights found using the affin-
ity microcolumns ranged from ±5 to ±20%, with an aver-
age precision of ±11%. This level of precision was actu-
ally slightly lower than noted earlier for carbamazepine 
but was sufficient for at least the preliminary screening of 
drug–protein interactions when using this type of affinity 
microcolumn.
3.5 HSA affinity microcolumns using silica monoliths 
versus silica particles
The final section of this study involved a comparison be-
tween affinity microcolumns that contained silica mono-
liths and similar affinity microcolumns that contained 7 
μm silica particles. R-Warfarin was used as the model an-
alyte in this comparison and an intermediate microcol-
umn length of 3 mm was employed for this work. The 
same preparation of HSA and the same immobilization 
method (i.e., the Schiff base technique) were used for 
all supports in this investigation. It has been noted ear-
lier that HSA silica monoliths can be prepared with up 
Figure 7. Retention factors obtained at various flow rates for 
injections of 20 μM R-warfarin obtained on (a) a 3 mm × 4.6 
mm i.d. HSA silica monolith column and (b) a 3 mm × 2.1 mm 
HSA column containing silica particles. The experimental con-
ditions are given in the text. The error bars represent a range 
of ±1 S.D. 
Figure 8. Plate height plots obtained for injections of 20 μM R 
-warfarin on a 3 mm × 4.6 mm i.d. HSA silica monolith or a 3 
mm × 2.1 mm i.d. HSA column containing silica particles. The 
experimental conditions are given in the text. The error bars 
represent a range of ±1 S.D. 
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to a third more protein per unit volume than can be ob-
tained with silica particles [23]. In this current study, a sil-
ica monolith with only a slightly higher content than the 
silica particles was used in preparing the HSA columns. 
The HSA content in the silica monolith was estimated to 
be 0.36 (±0.02) μmol/mL and the content in the column 
with silica particles was 0.34 (±0.02) μmol/ mL. As shown 
in Figure 7, the use of the same protein, immobilization 
method, and similar protein contents resulted in similar 
retention factors for R-warfarin on these columns, with an 
average retention factor that was 16% higher for the silica 
monolith.
Like the results noted earlier in Figure 7a for the HSA 
silica monoliths, the retention factors given in Figure 7b 
for R-warfarin on the HSA microcolumn packed with 7 
μm silica particles gave consistent results up to flow rates 
of 4.0 mL/min. The variation in the results in Figure 7b 
was ±7% between 0.1 and 4.0 mL/min, which was the 
same variation found in Figure 7a for data obtained using 
the HSA silica monolith. The precision of the retention 
factors measured on the column containing silica parti-
cles ranged from ±1.8 to ±14%, with an average of ±6%. 
This precision was slightly worse than noted for the HSA 
microcolumn based on a silica monolith, but indicated 
that the silica particle-based microcolumn could also be 
used to provide reasonably reproducible retention factors 
for drug–protein binding experiments. 
A larger difference between the microcolumns using 
a silica monolith or silica particles was seen when com-
paring their efficiencies (see Figure 8). Although the sil-
ica monolith gave consistent plate heights throughout the 
range of linear velocities that were sampled, the column 
containing silica particles gave a consistent increase in 
plate with linear velocity over the same range. These re-
sults agree with plate height plots that have been previ-
ously reported for R-warfarin on a 10 cm × 4.6 mm i.d. 
HSA silica monolith and an HSA column of a comparable 
size containing silica particles [23]. At the highest linear 
velocities that were used, the silica monolith gave plate 
heights that were almost five-fold lower than those for 
the HSA microcolumn with 7 μm silica particles (note: a 
smaller difference would be expected when using parti-
cles with a diameter of 3 or 5 μm). This difference gave 
the silica monolith a greater number of theoretical plates 
and greater efficiency at higher flow rates. This property, 
in turn, should make it easier to use affinity microcol-
umns based on silica monoliths at these higher flow rates 
for the rapid screening or characterization of drug–pro-
tein binding.
4 Conclusions
This report examined the development and use of affin-
ity microcolumns containing HSA silica monoliths for 
the high-throughput analysis of drug–protein interac-
tions. Studies using carbamazepine or warfarin as the in-
jected analyte indicated that microcolumns as short as 1 
to 3 mm could be used to provide reproducible estimates 
of retention factors or plate heights. Some benefits that 
were noted when using smaller columns for these mea-
surements included the lower retention times and lower 
back pressures that could be obtained versus traditional 
HPLC affinity columns. Another benefit was the smaller 
amount of protein that was required for column prepa-
ration. One disadvantage with decreasing column length 
was the lower precision that resulted in retention factor 
and plate height measurements. Another possible disad-
vantage that was not a problem in this particular study 
was the lower sample capacity of the shorter columns. 
A comparison was also made between HSA microcol-
umns containing 7 μm silica particles versus silica mono-
liths. It was found in work with R-warfarin that both 
types of supports could be used in HSA microcolumns 
for the determination of retention factors or plate heights 
in drug–protein binding studies. However, the better effi-
ciency of the silica monolith made this the preferred sup-
port for work in which higher flow rates or a larger num-
ber of theoretical plates are needed for the analysis of 
drug–protein interactions. The information provided in 
this report should be useful in creating and adapting af-
finity microcolumns that contain HSA or other proteins 
for drug–binding studies. The ability of these microcol-
umns to provide reproducible results in a short amount 
of time should be particularly appealing for the high-
throughput screening of drug–protein binding or in the 
rapid determination of percentage binding, binding af-
finity, or dissociation/association rates for proteins with 
drug candidates [41–43]. 
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